Spyre Therapeutics, Inc.
SYRE
Rangering i aksjer
#2339
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Aksjekurs
$93.87
Markedsverdi
$8.66B
Endring (1 dag)
2.70%
Endring (1 år)
303.74%
Land
US
Handel Spyre Therapeutics, Inc. (SYRE)
Kategori
Healthcare
P/E-forhold for Spyre Therapeutics, Inc. (SYRE)
P/E-forhold per October 2026 TTM: -40.32
Ifølge Spyre Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -40.32. Ved slutten av 2023 hadde selskapet en P/E på -0.44.
P/E-forholdshistorikk for Spyre Therapeutics, Inc. fra 2013 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | -40.32 | 666.60% |
| 2024 | -5.26 | 1,101.32% |
| 2023 | -0.44 | -3.18% |
| 2022 | -0.45 | -90.47% |
| 2021 | -4.75 | -8.60% |
| 2020 | -5.19 | 66.46% |
| 2019 | -3.12 | -11.30% |
| 2018 | -3.52 | 17.03% |
| 2017 | -3.01 | 53.08% |
| 2016 | -1.96 | -80.14% |
| 2015 | -9.89 | -23.46% |
| 2014 | -12.92 | 0.00% |
| 2013 | 0.00 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 28.78 | -171.38% |
US
|
|
| -28.36 | -29.67% |
US
|
|
| -24.57 | -39.07% |
AU
|
|
| 30.33 | -175.22% |
NL
|
|
| - | - |
CH
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.